# Ruishi Biomedical Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ruishi-biomedical-co

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.reistonebio.com.cn
- Total disclosed funding: $100M
- Latest round: Series A (May 9, 2022)
- Investors on record: 5

## About

Based in Shanghai, China, and founded in 2018, Reistone Biopharma operates as a biopharmaceutical company that focuses on developing medicines for immuno-inflammatory diseases. The company's co-founder and CEO, Min Wang Irwin was formerly a venture partner at Qiming Venture Capital. The company's Chief Medical Officer, Aik Goh is a UK General Medical Council (GMC) registered doctor, and worked in GSK for 10 years. The company has offices in Beijing and the US.

The company is executing global multi-center clinical programs of SHR 0302, including oral and topical dosage forms, for the treatment of Inflammatory Bowel Diseases (IBD) such as Ulcerative colitis (UC) and Crohn's disease (CD), as well as inflammatory skin diseases such as Atopic Dermatitis, Alopecia Areata and Vitiligo.

## Funding rounds

- Series A, May 9, 2022, $100M — Zero2IPO Ventures, Huagai Capital, Hanne Capital, Yinglian Health Industry Fund, Zhangjiang Haoheng Capital

## Investors

- Zero2IPO Ventures (https://capitalatlas.ai/funds/zero2ipo-ventures) — Series A
- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Series A
- Hanne Capital (https://capitalatlas.ai/funds/hanne-capital) — Series A
- Yinglian Health Industry Fund — Series A
- Zhangjiang Haoheng Capital (https://capitalatlas.ai/funds/zhangjiang-haoheng-capital) — Series A